WO2012175562A3 - Methylation and microrna markers of early-stage non-small cell lung cancer - Google Patents

Methylation and microrna markers of early-stage non-small cell lung cancer Download PDF

Info

Publication number
WO2012175562A3
WO2012175562A3 PCT/EP2012/061852 EP2012061852W WO2012175562A3 WO 2012175562 A3 WO2012175562 A3 WO 2012175562A3 EP 2012061852 W EP2012061852 W EP 2012061852W WO 2012175562 A3 WO2012175562 A3 WO 2012175562A3
Authority
WO
WIPO (PCT)
Prior art keywords
methylation
early
detecting
lung cancer
small cell
Prior art date
Application number
PCT/EP2012/061852
Other languages
French (fr)
Other versions
WO2012175562A2 (en
Inventor
Tarmo Annilo
Neeme TÕNISSON
Tõnu VOODER
Kaie KIROTAR
Urmo VÕSA
Kristjan VÄLK
Raivo KOLDE
Retlav ROOSIPUU
Jaak VILO
Andres Metspalu
Original Assignee
University Of Tartu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tartu filed Critical University Of Tartu
Publication of WO2012175562A2 publication Critical patent/WO2012175562A2/en
Publication of WO2012175562A3 publication Critical patent/WO2012175562A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention is related to a method for detecting neoplastic cells originating from lung tissue with DNA and RNA-based biomarkers whereas the method comprising steps of isolating DNA or RNA from lung tissue or remote body fluids, detecting the methylation state of DNA of one or more, and/or detecting the expression levels of one or more micro-RNAs, thereafter determining the presence of neoplastic cells by comparing the methylation level and/or expression level of the genes with the levels of same genes in non-neoplastic cells, whereas if the methylation or expression level in the cell differs from the normal methylation or expression level in the cell said cell is considered neoplastic. There have been identified genes with altered methylation and microRNAs with aberrant expression in NSCLC.
PCT/EP2012/061852 2011-06-21 2012-06-20 Methylation and microrna markers of early-stage non-small cell lung cancer WO2012175562A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161499578P 2011-06-21 2011-06-21
US61/499,578 2011-06-21

Publications (2)

Publication Number Publication Date
WO2012175562A2 WO2012175562A2 (en) 2012-12-27
WO2012175562A3 true WO2012175562A3 (en) 2013-02-28

Family

ID=46456526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/061852 WO2012175562A2 (en) 2011-06-21 2012-06-20 Methylation and microrna markers of early-stage non-small cell lung cancer

Country Status (1)

Country Link
WO (1) WO2012175562A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119934A2 (en) 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
ES2859645T3 (en) 2013-03-14 2021-10-04 Mayo Found Medical Education & Res Neoplasia detection
WO2014173905A2 (en) * 2013-04-23 2014-10-30 Institut D'investigació Biomèdica De Bellvitge (Idibell) Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides
CN104711338A (en) * 2013-12-12 2015-06-17 博奥生物集团有限公司 Use of miR-24 as reference gene of blood plasma/serum miRNA detection
EP4234722A3 (en) 2014-03-31 2023-09-20 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
EP3262190B1 (en) * 2015-02-24 2021-09-01 Ruprecht-Karls-Universität Heidelberg Biomarker panel for the detection of cancer
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
EP3274440A4 (en) 2015-03-27 2019-03-06 Exact Sciences Corporation Detecting esophageal disorders
CA2992790A1 (en) 2015-08-31 2017-03-09 Mayo Foundation For Medical Education And Research Detecting gastric neoplasm
EP3190191A1 (en) * 2016-01-11 2017-07-12 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Method and kit for the diagnosis of lung cancer
CN105664162B (en) * 2016-02-01 2019-11-05 成都望路医药技术有限公司 The molecular marked compound GRIK3 of rectal adenocarcinoma
CN105624324B (en) * 2016-03-31 2019-06-11 北京泱深生物信息技术有限公司 Hypophysoma diagnosis and treatment marker
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
KR102380690B1 (en) 2016-04-14 2022-03-29 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Detection method for pancreatic elevation dysplasia
WO2018009709A1 (en) * 2016-07-06 2018-01-11 Youhealth Biotech, Limited Lung cancer methylation markers and uses thereof
AU2018229294A1 (en) 2017-02-28 2019-09-26 Exact Sciences Corporation Detecting prostate cancer
CN106811532B (en) * 2017-03-03 2020-03-31 青岛泱深生物医药有限公司 Application of ACTA1 as tongue squamous carcinoma diagnosis and treatment marker
KR20200105661A (en) 2017-11-30 2020-09-08 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Breast cancer detection method
CN108753962A (en) * 2018-05-14 2018-11-06 丽水市人民医院 Purposes of the hsa-miR-130a in non-small cell lung cancer prognosis
CN114736968B (en) * 2022-06-13 2022-09-27 南京世和医疗器械有限公司 Application of plasma free DNA methylation marker in lung cancer early screening and lung cancer early screening device
WO2024007205A1 (en) * 2022-07-06 2024-01-11 何肇基 Method and system for establishing indicator for assessing degree of malignancy of tissue microenvironment, and method and system for using indicator for assessing degree of malignancy of tissue microenvironment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044331A2 (en) * 2000-11-29 2002-06-06 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009105549A2 (en) * 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044331A2 (en) * 2000-11-29 2002-06-06 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009105549A2 (en) * 2008-02-19 2009-08-27 Oncomethylome Sciences Sa Detection and prognosis of lung cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 2011 (2011-04-01), HWANG SANG-HYUN ET AL: "Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients", XP008155637, Database accession no. PREV201100278672 *
GALLARDO ELENA ET AL: "miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer", CARCINOGENESIS (OXFORD), vol. 30, no. 11, November 2009 (2009-11-01), pages 1903 - 1909, XP002682666, ISSN: 0143-3334 *
HOJOONG KIM ET AL: "Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 22, no. 12, 15 June 2004 (2004-06-15), pages 2363 - 2370, XP002641112, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.10.077 *
PFEIFER G P ET AL: "DNA methylation patterns in lung carcinomas", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHIA, PA, US, vol. 19, no. 3, 1 June 2009 (2009-06-01), pages 181 - 187, XP026066682, ISSN: 1044-579X, [retrieved on 20090220], DOI: 10.1016/J.SEMCANCER.2009.02.008 *
RAUCH T ET AL: "Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 104, no. 13, 27 March 2007 (2007-03-27), pages 5527 - 5532, XP002575619, ISSN: 0027-8424, [retrieved on 20070316], DOI: 10.1073/PNAS.0701059104 *
TAN WEIQI ET AL: "Aberrant miRNA methylation in tumors from surgically resected lung cancer patients and association with survival", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 51, April 2010 (2010-04-01), & 101ST ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; WASHINGTON, DC, USA; APRIL 17 -21, 2010, pages 993 - 994, XP008155736, ISSN: 0197-016X *

Also Published As

Publication number Publication date
WO2012175562A2 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
WO2012175562A3 (en) Methylation and microrna markers of early-stage non-small cell lung cancer
Acunzo et al. MicroRNA and cancer–a brief overview
Guancial et al. The evolving understanding of microRNA in bladder cancer
Mei et al. Systematic characterization of non‐coding RNAs in triple‐negative breast cancer
IL210026A0 (en) Serum or plasma microrna as biomarkers for non-small cell lung cancer
WO2011153254A3 (en) Prostate cancer associated circulating nucleic acid biomarkers
HK1200838A1 (en) 5-methoxy. 3-oh unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing 5-3-oh
WO2013006495A3 (en) Methods of predicting prognosis in cancer
WO2009114681A3 (en) Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
WO2010135692A3 (en) Mirna biomarkers of prostate disease
WO2012177947A3 (en) Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
Amer et al. Hsa-miR-195 targets PCMT1 in hepatocellular carcinoma that increases tumor life span
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
WO2009012263A3 (en) Tissue-specific micrornas and compositions and uses thereof
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Kelly et al. A review of expression profiling of circulating microRNAs in men with prostate cancer.
WO2009079548A3 (en) Down-regulation of gene expression using artificial micrornas
WO2011027019A3 (en) Method for the diagnosis and/or prognosis of acute renal damage
WO2012104340A3 (en) Markers of melanoma and uses thereof
NZ629538A (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
WO2011128900A3 (en) Early detection and staging of colorectal cancer using a panel of micro rnas
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
WO2008055158A3 (en) Microrna as biomarker in cancer
WO2012079046A3 (en) Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
WO2011097509A3 (en) Hypoxia-related gene signatures for cancer classification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12731361

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12731361

Country of ref document: EP

Kind code of ref document: A2